Cancer
Conditions
Brief summary
The change in speech perception in noise (measured with the Finnish matrix sentece test) from the baseline to the first follow-up visit at 3-4 months after the end the initial treatment
Detailed description
Long-term change in the speech perception in noise, Short- and long-term change in extended high frequency hearing, Hearing-related quality of life, Changes in Functional Assessment of Cancer Therapy - Cognitive Function questionnaire and in standardized neuropsychological tests
Interventions
DRUGCisplatin Accord 1 mg/ml infuusiokonsentraatti
DRUGliuosta varten
DRUGGemcitabine Accord 100 mg/ml infuusiokonsentraatti
DRUGliuosta varten.
DRUGUromitexan cum conservans 100 mg/ml injektioneste
DRUGliuos
DRUGHoloxan injektio-/infuusiokuiva-aine
DRUGEtoposide Accord 20 mg/ml Infuusiokonsentraatti
Sponsors
Turku University Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The change in speech perception in noise (measured with the Finnish matrix sentece test) from the baseline to the first follow-up visit at 3-4 months after the end the initial treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| Long-term change in the speech perception in noise, Short- and long-term change in extended high frequency hearing, Hearing-related quality of life, Changes in Functional Assessment of Cancer Therapy - Cognitive Function questionnaire and in standardized neuropsychological tests | — |
Countries
Finland
Outcome results
None listed